(HealthDay Information) — Hospitalized COVID-19 sufferers receiving no oxygen or low-flow oxygen have been extra prone to obtain medical enchancment inside 28 days in the event that they have been handled with remdesivir, in accordance with a examine printed on-line in Medical Infectious Ailments.
Brian T. Garibaldi, MD, from Johns Hopkins College in Baltimore, and colleagues retrospectively assessed the effectiveness of remdesivir for remedy of COVID-19. The evaluation included 18,328 sufferers hospitalized with confirmed COVID-19 (Feb. 23, 2020, via Feb. 11, 2021) who acquired no less than 1 dose of remdesivir and matched COVID-19 sufferers not receiving remdesivir.
The researchers discovered that 74% of remdesivir-treated sufferers had medical enchancment inside 28 days (median time of seven days) versus 68.3% of management sufferers (median time of 9 days). These handled with remdesivir have been considerably extra prone to obtain medical enchancment by 28 days (adjusted hazard ratio [aHR], 1.19; 95% confidence interval [CI], 1.16 to 1.22). Medical enchancment was extra prone to be achieved by 28 days for remdesivir-treated sufferers on no oxygen (aHR, 1.30; 95% CI, 1.22 to 1.38) or low-flow oxygen (aHR, 1.23; 95% CI, 1.19 to 1.27). For general mortality, there was no vital affect noticed (aHR, 1.02; 95% CI, 0.97 to 1.08). Nevertheless, remdesivir recipients on low-flow oxygen have been considerably much less prone to die than controls (aHR, 0.85 [95% CI, 0.77 to 0.92]; 28-day mortality, 8.4% for remdesivir sufferers versus 12.5% for controls).
Proceed Studying
“We noticed that remdesivir is greatest used as early as attainable, earlier than the affected person progresses to requiring excessive ranges of oxygen or intubation and mechanical air flow,” Garibaldi stated in an announcement. “Most sufferers who want that sort of superior respiratory help are probably previous the purpose the place antiviral therapies like remdesivir can be efficient.”
A number of authors disclosed monetary ties to pharmaceutical firms, together with Gilead, the producer of remdesivir.
Abstract/Full Text (subscription or payment may be required)
